The results of trastuzumab deruxtecan trials suggested differences in therapeutic effect between HER2-ultralow, defined as tumors with ≤ 10% of tumor cells showing faint/weak membrane staining, and HER2-null, defined as tumors completely lacking HER2 staining [6]. This evidence concerns the gene ERBB2 and neoplasm.